Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVD Lite in Newly Diagnosed Multiple Myeloma
NCT01782963Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2013
- Primary completion
- Dec 2016
- Countries
- 1
- Sponsor
- Massachusetts General Hospital
- Modality
- Modified Peptides, Orthosteric Ligands
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Massachusetts General Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Mar 2013; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment Arm
RVD Lite Regimen
03
Endpoints
Primary
Objective Response Rate
Secondary
Number of Participants With Grade 3 or Higher Treatment Related Adverse Events
Median Progression Free Survival
Median Overall Survival
Median Time to Response
Response Rate With Respect to Cytogenetic Characteristics
Mean Plasma Bortezomib Concentration
Pharmacogenomic Markers of Neuropathy
Beyond the preview
Go deeper on NCT01782963.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782963.